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Abstract
Background: Although there are many studies of the predictors of death in hepatocel-
lular carcinoma (HCC), most combine patients with and without cirrhosis and many
combine those with compensated and decompensated cirrhosis. Objective: To perform
a systematic review of the literature evaluating the predictors of death in patients with
cirrhosis and HCC and to evaluate whether the predictors differ between patients with
compensated and decompensated cirrhosis. Methods: Inclusion criteria: (i) publica-
tion in English, (ii) adult patients, (c) 480% of the patients had cirrhosis, (iv) follow-
up 46 months and (v) multivariable analysis. Quality was based on the accepted
quality criteria for prognostic studies. Results: Of the 1106 references obtained, 947
were excluded because they did not meet the inclusion criteria. A total of 23968
patients were included in 72 studies (median, 177/study); 77% male, median age 64,
55% Child–Pugh class A. The most robust predictors of death were portal vein
thrombosis, tumour size, a-foetoprotein and Child–Pugh class. Sensitivity analysis
using only 15 ‘good’ studies and 22 studies in which all patients had cirrhosis yielded
the same variables. In the studies including mostly compensated or decompensated
patients, the predictorswereboth liverandtumour related. However, these studies were
few and the results were not robust. Conclusions: This systematic review of 72 studies
shows that the most robust predictors of death in patients with cirrhosis and HCC are
tumour related and liver related. Future prognostic studies should include these
predictors and should be performed in speciﬁc patient populations to determine
whether speciﬁc prognostic indicators are more relevant at different stages of cirrhosis.
Hepatocellular carcinoma (HCC) is responsible for signiﬁcant
morbidity and mortality in cirrhosis. It commonly leads to
decompensation of cirrhosis and is one of the leading causes of
death in cirrhotic patients (1, 2). Identifying the accurate
prognostic indicators of death for HCC allows the provider to
counsel individual patients and also forms the basis of any
decision-making process. Most cases of HCC in the western
world occur in the setting of cirrhosis and, therefore, prognosis
is determined not only by factors related to the tumour but also
by factors related to cirrhosis. In fact, current prognostic
models for HCC include parameters of liver dysfunction and
parameters related to HCC (3–5). However, studies on the
prediction of death in HCC include patients both with and
without underlying cirrhosis, and this heterogeneity may
impact the clinical utility of current prognostic models.
Additionally, one could hypothesize that, as in cirrhosis not
associated with HCC (2), the prognostic factors for HCC would
be different in patients with underlying compensated vs.
decompensated cirrhosis, with factors related to the tumour
having a greater prognostic signiﬁcance in the former and
factors related to both tumour and liver disease being more
important in the latter. The purpose of this systematic review is
to evaluate the predictors of death in patients with HCC and
underlying cirrhosis to determine whether the predictors differ
between patients with compensated and decompensated
cirrhosis.
Methods
A Medline search was performed using the terms (survival
[ALL] OR mortality [ALL] OR predictor [ALL] OR prognosis
[ALL] OR prognostic [ALL] AND (multivariate OR Cox OR
Cox’s OR adjusted OR adjustment OR logistic [ALL]) [MESH]
AND hepatocellular carcinoma [MESH]. The search was car-
ried out in March 2008 and no lower date limit was set on the
search results. Additional studies were located by manual search
using references from retrieved articles.
Studies were selected using the following inclusion criteria:
(i) English language, (ii) inclusion of only adult patients, (iii)
established diagnosis of HCC, (iv) 480% of patients included
had cirrhosis – ifcirrhosis was not speciﬁcally mentioned, it was
assumed that the population was comprised of cirrhotic
patients if all patients in the study were classiﬁed into Child–
Pugh classes, (v) survival analysis was reported, (vi) multi-
variate analysis of prognostic indicators of mortality was
performed and (vii) patients in the study were either untreated
or the study included more than one type of therapy following
a local treatment protocol. Trials were excluded if they had
Re-use of this article is permitted in accordance with the Creative
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(o6 months), (iii) a single treatment option was being
analysed, (iv) randomized trials comparing two different thera-
pies, (v) the main predictive factor being studied was a tumour
histological feature (i.e. tumour staining) and (vi) abstract only
or full-text article not available. The rationale for excluding
trials with only a single treatment option was that as candidates
for particular treatment options may have varying prognoses,
this may have resulted in a biased inclusion of patients.
Required clinical data and data regarding study validity were
predeﬁned and collected for all studies meeting the inclusion
criteria.
Study validity was assessed using predeﬁned quality criteria,
as listed in Table 1 (2, 6–8).Because none of the trials met all the
quality criteria (Table 1), ‘good quality’ studies were arbitrarily
deﬁned as those that fulﬁlled all four of the following major
quality criteria: (i) enrollment of consecutive patients, (ii)
listing relevant baseline data, (iii) reporting the number of
deaths and (iv) the absence of overﬁtting (ratio of the number
of deaths/the number of variables 410). All ‘good quality’
studies documented the number of patients with cirrhosis.
An ‘advanced’ tumour was arbitrarily deﬁned as any of the
following: ‘multinodular’ tumours or tumours exceeding the
Milan criteria (one tumour 45cm or three tumors, with any
of them being 43cm) (9). In the analysis aimed at determin-
ing whether the prognostic variables differed between patients
with advanced vs. non-advanced tumours, studies including
mostly advanced tumours were deﬁned as those in which 66%
of the patients had advanced tumours and studies including
mostly non-advanced tumours were deﬁned as those in which
466% of the patients had non-advanced tumours. Decom-
pensated cirrhosis was deﬁned as a patient with Child–Pugh B
or C classiﬁcation. In the analysis aimed at determining
whether the prognostic variables differed between patients with
compensated vs. decompensated cirrhosis, studies including
mostly compensated patients were arbitrarily deﬁned as those
inwhich 466% of the patients were Child–Pugh A and studies
including mostly decompensated patients were arbitrarily de-
ﬁned as those inwhich 466% of the patients wereChild–Pugh
Bo rC .
The 1-, 2-, 3- and 5-year cumulative survivals and the ﬁnal
cumulative survival were recorded if present. The ﬁrst ﬁve
signiﬁcant prognostic indicators in each multivariate analysis
were recorded as were the number of studies evaluating each
variable. A sensitivity analysis was performed using the ‘good
quality’ studies and using the studies in which 100% of the
patients had cirrhosis.
Results
As shown in Figure 1, of the 1106 references identiﬁed through
a Medline search, 947 were excluded on analysis of the abstract
provided because they did not meet the inclusion and exclusion
criteria. Of the remaining 159 full-text articles, 88 were ex-
cluded, 84 because they did not meet the inclusion criteria (at
least 35 had combined cirrhotic and non-cirrhotic patients,
with o80% being cirrhotic and 10 did not even mention
whether there was underlying cirrhosis) and four because the
Table 1. Summary of the characteristics of 72 studies of the
predictors of mortality in hepatocellular carcinoma
Characteristics of studies n (%)
Aim
Explanatory 22 (31)
Predictive 50 (69)
Design
Prospective 21 (29)
Retrospective 51 (71)
Inception cohort 2 (3)
Patients were included consecutively 41 (57)
Inclusion and exclusion criteria deﬁned 34 (47)
Number of excluded patients speciﬁed 23 (32)
Diagnosis of hepatocellular carcinoma well deﬁned 59 (82)
Candidate variables identiﬁed a priori 38 (53)
Candidate variables included previously identiﬁed the
predictors of survival
72 (97)
Relevant baseline data shownw 43 (60)
Length of follow-up reported 21 (29)
Patients lost to follow-up reported 13 (18)
Number of deaths reported 43 (60)
Causes of death reported 29 (40)
Ratio of number of deaths/number of variables 410
(i.e. no overﬁtting)
28 (39)
Missing data reported 47 (65)
Results validated internally or externally 7 (10)
Geographical origin of the study
Japan 28 (39)
Italy 19 (26)
Thailand 5 (7)
Spain 3 (4)
Sites publishing   2 studiesz 17 (24)
‘Good’study deﬁned by the presence of these quality variables.
wAt a minimum, studies should have reported age, sex, presence and
aetiology of cirrhosis and Child–Pugh class or components.
zOther sites included Australia, Taiwan, Hong Kong, Germany, Portugal,
Kuwait, USA, France, Austria, Turkey, Greece, Belgium, Singapore and
China.
Articles identified by PubMed
search (n= 1106)
Articles retrieved for more
detailed evaluation (n= 159)  
Articles selected from search
for inclusion into systematic
review (n= 71). One study
included twice (two age groups
with separate analyses)
Total = 72 studies       
Articles excluded after abstract
review (n= 947)  
Articles excluded after review of
full publication (n= 88):  
￿ <80% had cirrhosis: 35
￿ Data on cirrhosis or Child–
   Pugh class unavailable: 10
￿ No multivariate analysis: 11
￿ Not survival analysis: 8
￿ Single therapy or randomized
   trial: 13
￿ Main predictive factor was 
   tumor histologic feature: 4
￿ Short term survival only: 2
￿ Full text unavailable: 4
￿ Review: 1          
Fig. 1. Trial ﬂow.
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meeting the criteria for inclusion in the review. One trial (46)
was included twice as it had two separate analyses for two
different age groups, bringing the total number of studies
reviewed to 72.
Description of the prognostic studies
Regarding the aim of the study, 69% (50/72) of the studies
were predictive studies, i.e. they assessed the prognostic value
of multiple variables without concern on the pathophysiology
of the variable, and 31% (22/72) were explanatory, i.e. a speciﬁc
variable was evaluated according to a biologically plausible
hypothesis (Table 1). Regarding the design of the study, 71%
were retrospective and only 29% were prospective. Only 57% of
the studies enrolled patients consecutively. The least commonly
fulﬁlled qualitycriteriawerethe presenceof an inception cohort
(3%), internal/external validation of results (10%) and report-
ing of loss to follow-up (18%). No study fulﬁlled all quality
criteria. Fifteen studies met our deﬁnition for a ‘good quality
study’, i.e. they fulﬁlled the four major predeﬁned quality criteria
(4, 21, 26, 31, 33, 34, 38, 44, 53, 56, 58, 66, 68, 71, 77). The
geographical origin of the majority of the studies was Japan or
Italy (Table 1). Eighty-two per cent of the articles outlined their
diagnostic criteria for HCC. This included various combina-
tions of compatible histology, radiology and a-foetoprotein
(AFP) investigations.
Description of patients included in the prognostic studies
Overall, 23968 patients were included in the 72 studies. Their
characteristics are reported in Table 2. The median number of
patients per trial was 177, with a range from 30 to 4525. The
median age was 66, with 71% males. Fifty-two of the included
studies explicitly stated the number of patients with cirrhosis.
Although the other 20 studies did not, they did divide all
patients by the Child–Pugh classiﬁcation which is, by conven-
tion, reserved for cirrhotic patients. None of these 20 studies
met our predeﬁned quality criteria.
Survival in the prognostic studies
As shown in Table 2, the median follow-up time was 21 months,
with a mortality rate of 69%. The median survival time was
16 months. The 1-, 3-year and ﬁnal cumulative survival were
66, 36 and 24% respectively. The median survival in studies
including patients with predominantly decompensated cirrho-
sis (n=3 studies with available data) (38, 54, 62) was 8 months
as compared with 29 months in those including patients with
predominantly compensated cirrhosis (n=4 studies) (39, 51,
59, 74). Twenty-eight studies reported the causes of death. The
most common cause of death was recorded as being related to
HCC in the majority (59%), followed by progression of liver
disease (28%) (Table 2).
Prognostic variables
A total of 79 variables were evaluated in these studies (Table 3).
The ﬁve most common independent predictors of death in
HCC were portal vein thrombosis, tumour size, AFP, Child–
Pugh class and bilirubin (Table 4). Of these, the variables that
were found to be most signiﬁcant in a larger number of studies
were portal vein thrombosis, tumour size and Child–Pugh class
(each of them evaluated in more than 30 studies and found to
be signiﬁcant in 450% of them). The Cancer of the Liver
Italian Program (CLIP) score was the sixth independent pre-
dictor found in 11/15 studies (24, 26, 34, 36, 45, 47, 53, 54, 58,
61, 65, 66, 72, 75, 79) evaluating the variable. Variables found to
be independently predictive of survival in at least one study are
shown in Table 5 and, of these, lack of therapy and performance
status are remarkable because they were found to be predictive
of death in over two-thirds of the 15 and eight studies in which
Table 2. Characteristics of hepatocellular carcinoma patients in-
cluded in 72 studies evaluating predicting the predictors of mortality
Variable
No. of studies
with available
information
Median [range]
(interquartile
range)
Sample size (patients
included/study)
72 177 [30–4525]
Age 66 64 [51–82]
% male 71 77 [63–93]
% cirrhosis 52 97 (90–100)
Aetiology of cirrhosis 68
Hepatitis C (%) 56 60 (38–81)
Alcohol (%) 31 16 (9–29)
Hepatitis B (%) 61 18 (11–40)
Mixed (%) 29 5 (2–9)
Other (%) 46 12 (7–18)
Child–Pugh class
A (%) 58 55 (45–65)
B (%) 53 33 (28–40)
C (%) 52 11 (7–18)
% with decompensated cirrhosis 60 45 (35–56)
% with advanced tumour 68 52 (45–58)
% with varices 9 49 (45–58)
Treatment
Curative (%) 51 34 (29–49)
Palliativew (%) 48 30 (22–48)
Untreated (%) 50 26 (12–56)
Otherz (%) 25 15 (4–50)
Follow-up period (months) 21 19 (12–28)
Mortality (%) 43 69 (57–81)
Causes of death 28
Hepatocellular carcinoma (%) 21 59 (35–74)
Progression of liver disease (%) 23 28 (18–56)
Variceal bleeding (%) 20 9 (6–15)
Sepsis (%) 7 5 (1–8)
Median survival time (months) 36 16 (5–22)
1-year cumulative survival (%) 46 66 (49–81)
2-year cumulative survival (%) 18 49 (28–56)
3-year cumulative survival (%) 32 36 (22–46)
5-year cumulative survival (%) 24 24 (15–30)
Final cumulative survival (%) 31 21 (13–29)
No. of variables assessed (total) 36 15 (11–19)
No, of deaths 43 121 (55–248)
No. variables entered on
multivariate analysis
66 7 (5–10)
No. variables independently
predictive of death
72 4 (2–4)
Liver transplantation, surgical resection or local ablative therapies
(percutaneous ethanol injection, radiofrequency ablation).
wTransarterial embolization or chemoembolization, systemic or hepatic
arterial chemotherapy.
zOther treatment modalities, treatment not mentioned or combination
therapy.
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evaluated werenot signiﬁcantly predictive of death in any study.
Whenonlythe15‘goodquality’studiesareanalysed(Table6),
the same most common predictors of death are observed as for
the overall analysis, i.e. Child–Pugh class, AFP, portal vein
thrombosis, CLIP score and tumour size. The most robust
predictors were Child–Pugh class, AFP and portal vein throm-
bosis. As the majority of the studies (89%) evaluating Child–
Pugh status divided patients by class (A, B, C) and not by score,
the term Child–Pugh class is utilized in this review.
When the 22 studies in which 100% of the patients had
cirrhosis are analysed (11, 12, 14, 19, 23, 24, 26, 27, 32, 35, 36,
38, 47, 52, 53, 60, 62, 68, 69, 71, 78, 79) (Table 7), the most
common predictors of death found in over three studies are
the CLIP score, tumours that were untreated, tumour size, the
Child–Pugh class, tumour number, AFP and portal vein
thrombosis.
The number of studies that included mostly compensated or
decompensated cirrhotic patients was small. However, as shown
in Table 8, in both groups of patients, the predictors of death
included both liver-related and tumour-related factors. When
patients were separated by advanced or non-advanced tumour
status, the most important predictors of death in patients with
advanced tumours were portal vein thrombosis, AFP, bilirubin
and lack of treatment (Table 9). The number of studies
analysing signiﬁcant predictors of death in patients with non-
advanced tumours was small.
Discussion
Hepatocellular carcinoma can arise in both non-cirrhotic and
cirrhotic livers.In the Orient, where hepatitis B or toxins arethe
most common underlying causes, HCC commonly arises in the
absence of cirrhosis (80, 81). In the west, where hepatitis C and
alcohol are the most common underlying liver diseases, HCC
arises mostly in the setting of cirrhosis (81–83). Prognosis is
predictably worse in patients with underlying cirrhosis (81, 84).
Even in patients with cirrhosis (without HCC), it has recently
been shown that the prognostic factors, survival and causes of
death differ signiﬁcantly between those with compensated and
decompensated cirrhosis (2) and that these two entities should
be considered separately both in clinical practice and in clinical
research (85). In fact, HCC is an independent predictorof death
in patients with decompensated cirrhosis (2).
Prognosis is an essential part of the assessment of patients
with HCC. It allows the patient to make important decisions,
Table 3. A list of all variables (n=79) evaluated as predictors of
death in 72 studies
Patient demographics (n=3)
Age, Gender, Ethnicity
Hepatic insufﬁciency (n=9)
Child–Pugh class, MELD, albumin, bilirubin, PT, ICG clearance,
LCSGJ liver damage scale
Cirrhosis, hepatic encephalopathy
Portal hypertension (n=3)
Ascites, varices
Platelets
Tumour factors (n=28)
Portal vein thrombosis, metastases, lymph node involvement,
gross HCC, tumour size, tumour number, tumour histology, tumour
stage, tumour echow, tumour marginz, tumour doubling time,
encapsulation‰, SUV ratio, AFP, AFP-L3, DCP, LAK, NK, p53, IL-8,
LINE-1, CRP, TGF-b, HGF, Milan criteriaz
Tumour location, cholinesterase, PIVKA-II
Hepatocellular carcinoma staging classiﬁcations (n=10)
CLIP score, LCSGJ stage, Okuda scale, BCLC scale, JIS scale,
Modiﬁed JIS score, combination of staging systems
GRETCH scale, CUPI scale, French score
Aetiological factors (n=6)
Alcohol, hepatitis B, hepatitis C, viral load, HBeAg
Genotype
Treatment (n=5)
Untreated, treatment modality, surgery, TACE, delayed treatment
Other (n=15)
Performance status, symptoms, mode of detection, urea,
creatinine, GGT, ALP, a-1 antitrypsin, centre of diagnosis, period of
surveillance
ALT, AST, haemoglobin, LDH, sodium
Variables in italics were among the ﬁrst ﬁve signiﬁcant variables on
multivariable analysis in at least one study.
Combination of number of tumours, size and extent of liver replace-
ment.
wEcho pattern on ultrasound.
zRegular tumour margin on ultrasound.
‰Presence of capsule on ultrasound.
zSingle tumour o5cm or three tumours each o3cm.
AFP, a-foetoprotein; AFP-L3, lens-culinaris agglutinin-reactive fraction of
AFP; ALP, alkaline phosphatase; ALT, alanino aminotransferase; AST,
aspartate aminotransferase, BCLC, Barcelona Clinic Liver Cancer; CLIP,
Cancer of the Liver Italian Program; CRP, C reactive protein; CUPI,
Chinese University Prognostic Index; DCP, des-gamma-carboxy pro-
thrombin; GGT, a ˜-glutamyl transpeptidase; GRETCH, Groupe d’Etude et
de Traitement du Carcinome Hepatocellulaire; HBeAg, hepatitis B envel-
ope antigen; HCC, hepatocellular carcinoma; HGF, hepatocyte growth
factor; ICG, indocyanine green clearance; IL, interleukin; JIS, Japanese
Integrated System; LAK, lymphokine-activated killer activity; LCSGJ, Liver
Cancer Study Group of Japan; LDH, lactate dehydrogenase; MELD,
model for end-stage liver disease; NK, natural killer activity; p53, anti-
p53 antibody; PIVKA-II, serum protein induced by vitamin K absence or
antagonist II; PT, prothrombin time; SUV, standardized uptake value on
positron emission tomography scan; TACE, transarterial chemoemboli-
zation; TGF-b, transforming growth factor-b.
Table 4. Variables (n=6) that were most commonly found to be
signiﬁcant predictors of death in hepatocellular carcinoma in
72 studies
Variable
No. of studies
in which variable
was among the
ﬁrst ﬁve signiﬁcant
variables
No. of
studies
evaluating
the variable
% of studies in
which the variable
was among the
ﬁrst ﬁve/total of
studies
Portal vein
thrombosis
22 32 69
Tumour size 20 33 61
AFP 20 41 49
Child–Pugh
class
18 33 55
Bilirubin 15 24 63
CLIP score 11 15 73
Cancer of the Liver Italian Program (consists of portal vein thrombosis,
tumour size, AFP and Child–Pugh class).
AFP, a-foetoprotein; CLIP, Cancer of the Liver Italian Program.
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such that different therapies can be investigated according to
risk. However, prognostic studies in HCC are often unsatisfac-
tory because patients included are heterogeneous, particularly
with regardto the presence(or absence)of underlying cirrhosis,
and the results are therefore not widely applicable. Because
most of the cases of HCC in the USA occur in the setting of
cirrhosis, it is important to determine the prognostic variables
in this subset of patients with HCC. Unfortunately, many of the
Table 5. Variables that were found to be signiﬁcant in one to 10 studies (n=55)
Variables signiﬁcant among the ﬁrst ﬁve in
two to 10 studies divided by the total studies
in which the variable was tested (%)
Variables signiﬁcant among the ﬁrst ﬁve in
only one study divided by the total studies in
which the variable was tested (%)
Variables signiﬁcant among
the ﬁrst ﬁve and tested in
only one study
Untreated 10/15 (67) Viral load 1/2 (50) Centre of diagnosis
Tumour number 8/22 (36) ICG 1/2 (50) Modiﬁed JIS score
Albumin 7/16 (44) Creatinine 1/3 (33) Lymph nodes
Performance status 6/8 (75) JIS scale 1/3 (33) CRP
Age 6/16 (38) Period of surveillance 1/3 (33) a-1 antitrypsin
Treatment modality 5/7 (71) MELD 1/5 (20) Tumour echo
Metastases 5/8 (63) Hepatitis C 1/6 (17) Tumour margin
Ascites 5/15 (33) GGT 1/7 (14) SUV ratio
DCP
a 4/6 (67) ALP 1/10 (10) Encapsulation
Gross HCC
b 4/9 (44) LAK
Tumour stage 4/14 (29) TGF-b
Okuda scale 4/15 (27) NK
LCSGJ liver damage 3/4 (75) HBeAg
Tumour histology 3/5 (60) Tumour doubling time
Symptoms 3/7 (43) p53
Alcohol 2/2 (100) IL-8
Surgery 2/2 (100) HGF
LCSGJ stage
c 2/2 (100) Combination of staging systems
AFP-L3 2/2 (100) LINE-1
BCLC scale 2/3 (67)
Milan criteria 2/3 (67)
Urea 2/3 (67)
TACE 2/3 (67)
Mode of detection 2/6 (33)
Varices 2/6 (33)
PT 2/8 (25)
Hepatitis B 2/10 (20)
AFP-L3, lens-culinaris agglutinin-reactive fraction of a-foetoprotein; ALP, alkaline phosphatase; BCLC, Barcelona Clinic Liver Cancer; CRP, C reactive protein;
DCP, des-gamma-carboxy prothrombin; GGT, a ˜-glutamyl transpeptidase; HBeAg, hepatitis B envelope antigen; HCC, hepatocellular carcinoma; HGF,
hepatocyte growth factor; ICG, indocyanine green clearance; IL, interleukin; JIS, Japanese Integrated System; LAK, lymphokine-activated killer activity;
LCSGJ,LiverCancerStudyGroupofJapan;MELD,modelforend-stageliverdisease;NK,naturalkilleractivity;p53,anti-p53antibody;PT,prothrombintime;
SUV, standardized uptake value on positron emission tomography scan; TACE, transarterial chemoembolization; TGF-b, transforming growth factor-b.
Table 6. Variables that were most commonly found to be signiﬁ-
cant predictors of death assessed in 15 ‘good’ quality studies
Variable
No. of good studies
in which variable
was among the ﬁrst
signiﬁcant ones
No. of
good studies
evaluating
the variable
% of studies in
which variable
was among the
ﬁrst ﬁve/total
studies
Child–Pugh
class
81 1 7 3
AFP 8 10 80
Portal vein
thrombosis
57 7 1
CLIP score 4 5 80
Tumour size 4 7 57
Good quality studies included all the four major quality criteria [relevant
baseline data shown, number of deaths reported, patients were included
consecutively and ratio of number of deaths/number of variables 410
(i.e. no overﬁtting)].
AFP, a-foetoprotein; CLIP, Cancer of the Liver Italian Program.
Table 7. Variables that were most commonly found to be signiﬁ-
cant predictors of death assessed in 22 studies in which 100% of the
patients included had cirrhosis
Variable
No. of good
studies in which
variable was
among the ﬁrst
signiﬁcant ones
No. of good
studies
evaluating
the variable
% of studies in
which variable
was among the
ﬁrst ﬁve/total
studies
CLIP score 6 6 100
Tumour size 5 7 71
Child–Pugh class 5 11 45
Tumour number 4 6 67
AFP 4 10 40
Portal vein
thrombosis
41 0 4 0
AFP, a-foetoprotein; CLIP, Cancer of the Liver Italian Program.
Liver International (2009)
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cirrhosis. In fact, of the 159 articles retrieved for this analysis, at
least 45 (28%) were excluded because more than 20% of the
patients did not have cirrhosis or the presence (or absence) of
cirrhosis was not mentioned. Even within the 72 studies
selected for analysis, only 22 (31%) of them clearly stated that
they included only patients with cirrhosis.
One of the strengths of this systematic review is that it
analysed predictors of death in HCC, speciﬁcally in studies in
which Z80% of the patients had underlying cirrhosis. Further-
more, it aimed to analyse whether the predictors differed in
patients with compensated vs. decompensated cirrhosis.
Despite methodological problems in the evaluated studies
(none met all quality criteria and only 21% of them met
important quality criteria), this systematic review allowed for
the identiﬁcation of the ‘robust’ predictors of death. As could
have probably been predicted, these were both tumour related
(portal vein thrombosis, tumour size and AFP) and cirrhosis
related (mainly, the Child–Pugh class). The strength or the
robustness of a predictor is given by the ratio between the
numberof studies inwhich eachvariable was signiﬁcant andthe
number of studies in which it was assessed. With a larger
number of studies, a large ratio is an indirect measure of the
validity as each study that conﬁrms the predictive value of a
variable provides indirect proof of its validity (2). This robust-
ness, which is independent of the quality of the studies, was
particularly true for portal vein thrombosis, tumour size and
Child–Pugh class, each of which was evaluated in more than 30
studies with a ratio 450%, i.e. more than half of the studies
proved them to be among the ﬁrst ﬁve most signiﬁcant
variables on a multivariable analysis. Importantly, the same
parameters were the most frequent signiﬁcant variables when
only the studies in which 100% of the patients included had
cirrhosis and when ‘good’ quality studies were analysed. In the
analysis of good quality studies, one of the most robust
predictors of death was the AFP.
Interestingly, one of the most commonly used HCC staging
systems, the CLIP system (4), includes all four of these
predictors (portal vein thrombosis, tumour size, Child–Pugh
class and AFP) and, in fact, the CLIP staging system itself was
identiﬁed as the sixth most common predictor of mortality,
being among the ﬁrst ﬁve signiﬁcant variables in 11/15 studies
(73%). Six of the 11 studies identifying the CLIP score as an
independent predictor were of Italian origin (24, 26, 36, 47,
53, 72). Another commonly used HCC staging system, and
the one recommended in recently published guidelines (81), is
the Barcelona Clinic Liver Cancer (BCLC) system (5), which
was onlyevaluated in three studies, but was neverthelessfound
to be among the ﬁrst ﬁve signiﬁcant variables in two (67%) of
them. This staging system also includes three of the predictors
(tumour size, Child–Pugh class and portal vein thrombosis).
Although it does not include AFP, the BCLC staging system
has the advantage of including other parameters such as
performance status (found to be an important predictor in
6/8 or 75% of the studies in which it was assessed) and,
importantly, of tailoring other prognostic factors to different
tumour stages (early vs. intermediate/advanced) and to
Child–Pugh class. For example, portal pressure, as determined
by the hepatic venous pressure gradient, which was not
directly evaluated in any of the studies in this analysis, was
shown to be an independent predictor of death in early stages
(patients subjected to resection) (86, 87) and is included in the
BCLC system but only in Child A patients with resectable
tumours (5). In the BCLC multivariable analysis study that
was performed to identify the predictors of death in inter-
mediate/advanced stages, an AFP of 435ng/ml was not
signiﬁcant on univariate analysis (23), whereas in the CLIP
staging system an AFP of 4400ng/dl had an independent
Table 8. Variables signiﬁcant in studies including mostly compensated or mostly decompensated patients
Compensated cirrhosis (13 studies) Decompensated cirrhosis (5 studies)
Variable
No. of signiﬁcant
studies
No. of studies
evaluated % Variable
No. of signiﬁcant
studies
No. of studies
evaluated %
DCP 4 5 80 Tumour size 2 2 100
Bilirubin 4 5 80 AFP 2 2 100
Child–Pugh class 4 7 57 Albumin 2 3 67
AFP 4 11 36
CLIP 3 4 75
Treatment received 3 4 75
Tumour size 3 4 75
AFP, a-foetoprotein; CLIP, Cancer of the Liver Italian Program; DCP, des-gamma-carboxy prothrombin.
Table 9. Variables signiﬁcant in studies including mostly advanced tumours or mostly non-advanced tumours
Advanced tumours (15 studies) Non-advanced tumours (7 studies)
Variable
No. of signiﬁcant
studies
No. of studies
evaluated % Variable
No. of signiﬁcant
studies
No. of studies
evaluated %
Portal vein
thrombosis
6 9 67 Albumin 2 2 100
AFP 5 8 63 Tumour size 2 2 100
Bilirubin 4 6 67 DCP 2 2 100
Untreated 4 6 67 Age 2 3 67
AFP, a-foetoprotein; CLIP, Cancer of the Liver Italian Program; DCP, des-gamma-carboxy prothrombin.
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prognostic utility of AFP is unclear in part due to the use of
heterogeneous cut-off levels and also due to its variable
sensitivity (88, 89). For example, in a recent study of 1158
patients (60% Child–Pugh A), even though the speciﬁcity of
an AFP level 4600ng/ml in predicting survival was 93%, its
sensitivity was only 23% (89).
Therefore, although the BCLC model has been reported to be
superior to alternate models for the prediction of survival in
HCC, including the Okuda, CLIP, tumour node metastasis,
Japanese Integrated System, Groupe d’Etude de Traitement du
Carcinoma Hepatocellulaire and Chinese University Prognostic
Index models (61, 67), three of which include the AFP, it would
be interesting to see whether the AFP (as a continuous variable)
adds to the prognostic value of the BCLC. The appropriate cut-
off level and the group of patients in which the AFP may be
helpful remains to be determined, although our analysis would
suggest that it appears to be more useful in advanced tumour
stages (Table 9).
The importance of determining prognosis at different stages
of cirrhosis cannot be overemphasized (2). We had hypothe-
sized that in the compensated patients factors related to the
tumour would be more important, whereas in the decompen-
sated patient, both liver- and tumour-related factors would be
important. However, in a subanalysis of studies including
mostly patients with compensated or decompensated cirrhosis
(Table 8), both tumour-related and cirrhosis-related predictors
appeared to be predictive of death in both groups. However, the
number of studies is too small to draw ﬁrm conclusions,
particularly regarding patients with mostly decompensated
cirrhosis and those with mostly non-advanced tumour stage.
Our study is limited by the design and prognostic parameters
chosen in each of the studies included in this analysis as well as
the heterogeneous group of patients included with both treated
and untreated tumours. Furthermore, although the choice of the
66% cut-off for the deﬁnition of ‘mostly decompensated cirrho-
sis’ or ‘mostly non-advancedtumour’ was inpartarbitrary, itcan
be justiﬁed because even at this cut-off there were too few studies
available in the 466% non-advanced tumour or 466%
decompensated cirrhosis categories to obtain deﬁnitive results.
Future studies on the prognostic indicators of HCC should
include patients either with or without cirrhosis. Studies that
will apply to patients with HCC seen in western countries
should include only patients with cirrhosis and the prognostic
variables should be assessed separately for the different stages of
cirrhosis, at a minimum, separating those with compensated
and those with decompensated cirrhosis. The study quality
should be optimized by incorporating most, if not all, of the
criteria listed in Table 1. Additionally, parameters identiﬁed by
the majority of the studies included in this analysis should be
included in such studies.
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